For years, we’ve always known the brain interface race to belong to Silicon Valley by default. We have all seen a headline about Elon Musk’s Neuralink. The technology attracted billions in funding and created such an aura of inevitability that we all assumed the first commercially available brain chip would have a Californian zip code. But, on the 13th of March, 2026, a Shanghai startup most people had never heard of rewrote that story.
Neuracle Medical Technology released NEO, which just became the first invasive brain-computer interface (BCI) product in history to get full commercial approval from a national regulator.
The startup got a proper product license with their product being sold to patients, and already covered by China’s national health insurance.
NEO is the first invasive brain-computer interface product cleared by any national regulator for commercial use, anywhere in the world. Neuralink, Synchron, and every comparable Western device remain in clinical trials.
What Is NEO, and How Does It Work?
NEO is roughly the size of a coin. It was developed jointly by Neuracle Medical Technology (a Shanghai based startup), and researchers at the School of Biomedical Engineering at Tsinghua University in Beijing.
The procedure to place the chip inside the skull takes roughly ninety minutes. The chip’s eight sensors sit on the dura mater, which is the brain’s outer protective membrane, and they don’t touch the brain itself. All a patient has to do is imagine moving their hand, and NEO will pick up the resulting neural signals and wirelessly relay them to an external computer.
The computer then decodes the signals and sends commands to a pneumatic robotic glove the patient wears on their hand. The chip translates intention into movement. A patient can just think of picking up a cup of tea, and the hand closes around a cup.
A patient named Dong in MIT Technology Review’s reporting, gave this description on the ninth day of training: “My right hand successfully grabbed a ball without the glove. That was a miraculous moment.”
What Did China’s Regulator Actually Approve?
On the 3rd of March, 2026, China’s National Medical Products Administration (NMPA) approved a Class III medical certificate for NEO, with Class III being the country’s highest regulatory classification. Specific criteria must be followed. The patients must be between the ages of 18 and 60, with quadriplegia caused by cervical spinal cord injuries, and retaining some upper arm function but still unable to grip objects.
NEO was used in a total of 36 clinical procedures: four early feasibility trials and 32 multi-center trials and these were conducted under Good Clinical Practice (GCP) standards.
Some of the supporting data remains in a preprint that has not yet completed full peer review, but the results are promising
Every single one of those 36 patients showed improvements in grasping objects. Some showed signs of neural remodeling, which means that their brains began reorganizing around the device over time.
NEO vs. Neuralink: The Design Choice That Won the Race
The single biggest reason NEO cleared regulators ahead of Neuralink likely comes down to one engineering decision: where to put the sensors.
Neuralink’s N1 chip fires ultra-thin electrodes directly into the cortex, the brain’s outermost layer of neural tissue. The signal quality is potentially superior. But piercing brain tissue means higher surgical risk, greater infection exposure, and the very real problem of scar tissue building up around the electrodes over time, degrading signal quality as years pass. Getting the FDA comfortable with that risk profile has proven to be, as Neuralink discovered in 2022 when the FDA initially rejected its trial application, a slow and methodical process.
NEO’s sensors sit on the dura mater and that means that they never contact the brain directly. Avinash Singh, a BCI researcher at the University of Technology Sydney, has described this as a significantly less invasive design that contributed to NEO’s faster regulatory path. It is a conscious trade-off: somewhat lower signal resolution in exchange for a much cleaner safety profile and, it turns out, a much faster route to market.
Mao Ying, president of Huashan Hospital at Fudan University, put it precisely: the system achieves stable acquisition of brain signals through minimally invasive implantation outside the dura mater, without contacting brain tissue or damaging neurons, while accurately decoding patients’ motor intentions. In plain English: all the signal, none of the holes in the brain.
Where Is Neuralink Right Now?
To be fair, Neuralink isn’t asleep in a corner somewhere. Scientific American reports that 21 participants were enrolled in its human trial as of January 2026. Its first recipient, Noland Arbaugh, has demonstrated the ability to control a computer cursor using thought alone. Other American startups including Synchron and Paradromics are running their own promising trials.
But Neuralink is still a trial and NEO is a product. As of March 2026, patients in China can go to a hospital, pay for the procedure, and receive a NEO implant on a commercial basis.
The FDA is right to be cautious. Piercing someone’s brain cortex carries real risks that should be addressed before a product becomes commercially available. China won the race because they designed around those concerns rather than trying to argue past them.
Neuralink: 21 trial participants as of January 2026. NEO: full commercial approval, Class III certification, national health insurance coverage, prescriptions available at hospitals.
China’s Playbook for Brain Technology
NEO’s science is definitely genuine, but there’s something other than scientific merit that helped the company get a foot through the door. The Chinese government decided, at the highest levels of policy, that brain-computer interfaces are a strategic national priority.
China’s five-year plan for 2026 to 2030, which was published on the same day Neuracle received its approval, designates BCI as one of six key industries important to the country’s future technology competitiveness, alongside quantum technology and humanoid robots, according to MIT Technology Review. Shanghai alone has cultivated 60 companies dedicated to BCI research and development.
The Chinese government backed trials and funded the research. It ran the fast-tracked approval pathway, then proceeded to publish the five-year plan the same morning of the approval (in a very calculated move).
China has done something similar to this before with electric vehicles, solar panels, and more.
The brain-computer interface market appears to be the next industry where state coordination is being used to leapfrog competitors who are moving at the pace of venture capital and cautious regulators.
What Does the World’s First Commercial Brain Chip Actually Mean?
For patients with cervical spinal cord injuries, the immediate practical meaning is substantial. Effective treatments for that condition have been, as Digital Watch Observatory notes, extremely limited for decades. A device that allows someone who cannot grip objects to do so again at home and independently, within a month of surgery, is nothing short of groundbreaking.
The broader geopolitical meaning is harder to miss. Brain-computer interface technology is not just a medical device market. It is foundational infrastructure for a future in which the boundary between human cognition and machine intelligence gets blurry. The country that builds the dominant clinical infrastructure, manufacturing base, and regulatory framework for this technology first will have an enormous structural advantage as the applications multiply.
China just took a meaningful lead in that direction. The research team has already signaled its next target: patients paralyzed by cerebral ischemic strokes, with expanded trials planned before the end of 2026.
The Race Is On
NEO is not the final chapter of the brain-chip story. It is the chapter where the technology stopped being a research project and became something a patient could ask a doctor about. That shift, from trial to prescription pad, is a bigger deal than any technical benchmark.
Elon Musk built the narrative around brain-computer interfaces. He deserves credit for that. He turned a niche field of neuroscience into something the general public actually talks about. But Neuracle Technology, backed by Tsinghua researchers and a state that decided to win this race explicitly, built the first device the market is actually allowed to buy.
For the patients who have spent years not waiting for the most spectacular chip, but for any chip they are allowed to use, that difference is not academic. It is everything.
Featured Image: Mirella Callage
Sources
Nature: China approves brain chip to treat paralysis (March 2026)
MIT Technology Review: China has approved the world’s first invasive brain-computer chip (June 2026)
Scientific American: China just approved its first brain implant for commercial use (March 2026)
Bloomberg: China Approves First Brain Implant for Commercial Use (March 2026)
Xinhua: China grants world’s first market approval for invasive BCI product (March 2026)
BrainFacts.org: In a First, China Approves Brain Implant for Commercial Use (April 2026)
People’s Daily: China approves world’s first implantable brain-computer interface (April 2026)
Digital Watch Observatory: China approves world-first brain chip to treat paralysis (March 2026)
Leave a Reply